{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T07:11:19Z","timestamp":1782371479990,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Haploidentical stem cell transplantation (haplo-HSCT) with post-transplant cyclophosphamide (PTCy) is a therapeutic option for secondary acute myeloid leukemia (sAML). The study aimed to compare peripheral blood stem cells (PBSC)\n                    <jats:italic>vs<\/jats:italic>\n                    . bone marrow (BM) as a graft source for haplo-HSCT with PTCy in patients with sAML in first complete remission. A total of 554 patients were included, BM\u2009=\u2009136, PBSC\u2009=\u2009418. Median follow-up was 3 years. The median year of transplant was 2018 (range, 2010\u20132021). The antecedent hematological disease was myelodysplastic syndrome \/myeloproliferative neoplasms in most patients. Patients in the BM group were younger, median age 59.2 vs. 61.7 years (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.008), and received myeloablative conditioning more frequently (66.4%\n                    <jats:italic>vs<\/jats:italic>\n                    . 47.4%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Time from diagnosis to haplo-HSCT was 5.3\n                    <jats:italic>vs<\/jats:italic>\n                    . 4.8 months, respectively (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.019). Performance status, cytogenetic risk, gender, cytomegalovirus serostatus, and donor age did not differ. There were no differences between the groups with respect to main transplantation outcomes. In conclusion, outcomes of haplo-HSCT with PTCy in sAML with either PBSC or BM grafts are similar, with no differences in major transplantation outcomes.\n                  <\/jats:p>","DOI":"10.1038\/s41409-026-02823-2","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T17:11:21Z","timestamp":1774458681000},"page":"559-568","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Peripheral blood stem cells versus bone marrow graft for non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP\/EBMT"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0763-1265","authenticated-orcid":false,"given":"Arnon","family":"Nagler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5897-3919","authenticated-orcid":false,"given":"Ryszard","family":"Swoboda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allain-Thibeault","family":"Ferhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5684-9447","authenticated-orcid":false,"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariya","family":"Koc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Raiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5361-5613","authenticated-orcid":false,"given":"Alessandro","family":"Busca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Pavlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4117-7991","authenticated-orcid":false,"given":"Stefania","family":"Bramanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maija","family":"It\u00e4l\u00e4-Remes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Colorado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4274-3895","authenticated-orcid":false,"given":"Jan","family":"Vydra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9589-4136","authenticated-orcid":false,"given":"Alexander","family":"Kulagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7171-4997","authenticated-orcid":false,"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6934-4619","authenticated-orcid":false,"given":"Jaime","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0873-0123","authenticated-orcid":false,"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"2823_CR1","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","volume":"125","author":"RC Lindsley","year":"2015","unstructured":"Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125:1367\u201376.","journal-title":"Blood"},{"key":"2823_CR2","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","volume":"33","author":"LS Granfeldt Ostgard","year":"2015","unstructured":"Granfeldt Ostgard LS, Medeiros BC, Sengelov H, Norgaard M, Andersen MK, Dufva IH, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: A National Population-Based Cohort Study. J Clin Oncol. 2015;33:3641\u20139.","journal-title":"J Clin Oncol"},{"key":"2823_CR3","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/ajh.23908","volume":"90","author":"E Huleg\u00e5rdh","year":"2015","unstructured":"Huleg\u00e5rdh E, Nilsson C, Lazarevic V, Garelius H, Antunovic P, Rangert Derolf \u00c5, et al. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: A report from the Swedish Acute Leukemia Registry. Am J Hematol. 2015;90:208\u201314.","journal-title":"Am J Hematol"},{"key":"2823_CR4","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.hoc.2019.11.003","volume":"34","author":"ES Winer","year":"2020","unstructured":"Winer ES. Secondary Acute Myeloid Leukemia: A Primary Challenge of Diagnosis and Treatment. Hematol Oncol Clin North Am. 2020;34:449\u201363.","journal-title":"Hematol Oncol Clin North Am"},{"key":"2823_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1182\/blood.2019000943","volume":"136","author":"AJ Dunbar","year":"2020","unstructured":"Dunbar AJ, Rampal RK, Levine R. Leukemia secondary to myeloproliferative neoplasms. Blood. 2020;136:61\u201370.","journal-title":"Blood"},{"key":"2823_CR6","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, Dinardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel on behalf of ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"2823_CR7","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1182\/blood.2024025409","volume":"144","author":"H D\u00f6hner","year":"2024","unstructured":"D\u00f6hner H, DiNardo CD, Appelbaum FR, Craddock C, Dombret H, Ebert BL, et al. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024;144:2169\u201373.","journal-title":"Blood"},{"key":"2823_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32103-8","volume":"13","author":"Y Tazi","year":"2022","unstructured":"Tazi Y, Arango-Ossa JE, Zhou Y, Bernard E, Thomas I, Gilkes A, et al. Unified classification and risk-stratification in Acute Myeloid Leukemia. Nat Commun. 2022;13:4622.","journal-title":"Nat Commun"},{"key":"2823_CR9","doi-asserted-by":"publisher","first-page":"4989","DOI":"10.1182\/bloodadvances.2021006468","volume":"6","author":"GL Uy","year":"2022","unstructured":"Uy GL, Newell LF, Lin TL, Goldberg SL, Wieduwilt MJ, Ryan RJ, et al. Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and\/or secondary AML. Blood Adv. 2022;6:4989\u201393.","journal-title":"Blood Adv"},{"key":"2823_CR10","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1182\/blood-2009-10-249128","volume":"115","author":"MR Litzow","year":"2010","unstructured":"Litzow MR, Tarima S, Perez WS, Bolwell BJ, Cairo MS, Camitta BM, et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood. 2010;115:1850\u20137.","journal-title":"Blood"},{"key":"2823_CR11","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.bbmt.2018.04.008","volume":"24","author":"S Sengsayadeth","year":"2018","unstructured":"Sengsayadeth S, Labopin M, Boumendil A, Finke J, Ganser A, Stelljes M, et al. Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study. Biol Blood Marrow Transpl. 2018;24:1406\u201314.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2823_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0296-3","volume":"10","author":"A-K Schmaelter","year":"2020","unstructured":"Schmaelter A-K, Labopin M, Soci\u00e9 G, It\u00e4l\u00e4-Remes M, Blaise D, Yakoub-Agha I, et al. Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia. Blood Cancer J. 2020;10:26.","journal-title":"Blood Cancer J"},{"key":"2823_CR13","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/s41409-022-01825-0","volume":"57","author":"A Nagler","year":"2022","unstructured":"Nagler A, Ngoya M, Jacques-Emmanuel G, Labopin M, Kr\u00f6ger N, Soci\u00e9 G, et al. Trends in the outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT. Bone Marrow Transpl. 2022;57:1788\u201396.","journal-title":"Bone Marrow Transpl"},{"key":"2823_CR14","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1053\/j.seminoncol.2012.09.005","volume":"39","author":"L Luznik","year":"2012","unstructured":"Luznik L, O\u2019Donnell PV, Fuchs EJ. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol. 2012;39:683\u201393.","journal-title":"Semin Oncol"},{"key":"2823_CR15","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1182\/blood-2015-01-623991","volume":"125","author":"SR McCurdy","year":"2015","unstructured":"McCurdy SR, Kanakry JA, Showel MM, Tsai HL, Bolanos-Meade J, Rosner GL, et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose post-transplantation cyclophosphamide. Blood. 2015;125:3024\u201331.","journal-title":"Blood"},{"key":"2823_CR16","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/s41423-020-00597-1","volume":"18","author":"H Guo","year":"2021","unstructured":"Guo H, Chang YJ, Hong Y, Xu LP, Wang Y, Zhang XH, et al. Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation. Cell Mol Immunol. 2021;18:1172\u201385.","journal-title":"Cell Mol Immunol"},{"key":"2823_CR17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13045-023-01450-4","volume":"16","author":"A Nagler","year":"2023","unstructured":"Nagler A, Labopin M, Blaise D, Raiola AM, Corral LL, Bramanti S, et al. Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP\/EBMT. J Hematol Oncol. 2023;16:58.","journal-title":"J Hematol Oncol"},{"key":"2823_CR18","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1182\/bloodadvances.2024012798","volume":"8","author":"A Nagler","year":"2024","unstructured":"Nagler A, Labopin M, Tischer J, Raiola AM, Kunadt D, Vydra J, et al. Haploidentical transplantation in primary refractory\/relapsed secondary vs de novo AML: from the ALWP\/EBMT. Blood Adv. 2024;8:4223\u201333.","journal-title":"Blood Adv"},{"key":"2823_CR19","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","volume":"14","author":"L Luznik","year":"2008","unstructured":"Luznik L, O\u2019Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, post-transplantation cyclophosphamide. Biol Blood Marrow Transpl. 2008;14:641\u201350.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2823_CR20","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41409-025-02524-2","volume":"60","author":"JR Passweg","year":"2025","unstructured":"Passweg JR, Baldomero H, Atlija M, Kleovoulou I, Witaszek A, Alexander T, et al. The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT. Bone Marrow Transpl. 2025;60:519\u201328.","journal-title":"Bone Marrow Transpl"},{"key":"2823_CR21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13045-023-01515-4","volume":"17","author":"C Lacan","year":"2024","unstructured":"Lacan C, Lambert J, Forcade E, Robin M, Chevallier P, Loron S, et al. Bone marrow graft versus peripheral blood graft in haploidentical hematopoietic stem cells transplantation: a retrospective analysis in 1344 patients of the SFGM-TC registry. J Hematol Oncol. 2024;17:2.","journal-title":"J Hematol Oncol"},{"key":"2823_CR22","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1200\/JCO.2017.72.8428","volume":"35","author":"A Bashey","year":"2017","unstructured":"Bashey A, Zhang MJ, McCurdy SR, St Martin A, Argall T, Anasetti C, et al. Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-Cell-replete haploidentical donor transplantation using post-transplant cyclophosphamide. J Clin Oncol. 2017;35:3002\u20139.","journal-title":"J Clin Oncol"},{"key":"2823_CR23","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1002\/cncr.31228","volume":"124","author":"A Ruggeri","year":"2018","unstructured":"Ruggeri A, Labopin M, Bacigalupo A, G\u00fclbas Z, Koc Y, Blaise D, et al. Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using post-transplantation cyclophosphamide. Cancer. 2018;124:1428\u201337.","journal-title":"Cancer"},{"key":"2823_CR24","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.critrevonc.2018.05.017","volume":"133","author":"X Yu","year":"2019","unstructured":"Yu X, Liu L, Xie Z, Dong C, Zhao L, Zhang J, et al. Bone marrow versus peripheral blood as a graft source for haploidentical donor transplantation in adults using post-transplant cyclophosphamide: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2019;133:120\u20138.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2823_CR25","first-page":"1003.e1","volume":"27","author":"RS Mehta","year":"2021","unstructured":"Mehta RS, Saliba RM, Alsfeld LC, Jorgensen JL, Wang SA, Anderlini P, et al. Bone marrow versus peripheral blood grafts for haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide. Transpl Cell Ther. 2021;27:1003.e1\u20131003.e13.","journal-title":"Transpl Cell Ther"},{"key":"2823_CR26","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1002\/ajh.27343","volume":"99","author":"R Devillier","year":"2024","unstructured":"Devillier R, Galimard JE, Blaise D, Raiola AM, Bramanti S, Grillo G, et al. Peripheral blood stem cell versus bone marrow graft for patients \u226560\u2009years undergoing reduced intensity conditioning haploidentical transplantation for acute myeloid leukemia in complete remission: An analysis of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2024;99:1250\u20136.","journal-title":"Am J Hematol"},{"key":"2823_CR27","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1182\/bloodadvances.2021005335","volume":"6","author":"D Mart\u00ednez-Cuadr\u00f3n","year":"2022","unstructured":"Mart\u00ednez-Cuadr\u00f3n D, Meg\u00edas-Vericat JE, Serrano J, Mart\u00ednez-S\u00e1nchez P, Rodr\u00edguez-Arbol\u00ed E, Gil C, et al. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. Blood Adv. 2022;6:1278\u201395.","journal-title":"Blood Adv"},{"key":"2823_CR28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2991\/chi.d.191207.001","volume":"2","author":"AS Kanate","year":"2019","unstructured":"Kanate AS, Nagler A, Savani B. Summary of Scientific and Statistical Methods, Study Endpoints and Definitions for Observational and Registry-Based Studies in Hematopoietic Cell Transplantation. Clin Hematol Int. 2019;2:2\u20134.","journal-title":"Clin Hematol Int"},{"key":"2823_CR29","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","volume":"367","author":"C Anasetti","year":"2012","unstructured":"Anasetti C, Logan BR, Lee SL, Waller EK, Weisdorf DJ, Wingard JR, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367:1487\u201396.","journal-title":"N Engl J Med"},{"key":"2823_CR30","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3324\/haematol.2015.135699","volume":"101","author":"BN Savani","year":"2016","unstructured":"Savani BN, Labopin M, Blaise D, Niederwieser D, Ciceri F, Ganser A, et al. Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT. Haematologica. 2016;101:256\u201362.","journal-title":"Haematologica"},{"key":"2823_CR31","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1080\/17474086.2023.2273847","volume":"16","author":"K Maurer","year":"2023","unstructured":"Maurer K, Soiffer RJ. The delicate balance of graft versus leukemia and graft versus host disease after allogeneic hematopoietic stem cell transplantation. Expert Rev Hematol. 2023;16:943\u201362.","journal-title":"Expert Rev Hematol"},{"key":"2823_CR32","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.beha.2013.10.010","volume":"26","author":"DJ Weisdorf","year":"2013","unstructured":"Weisdorf DJ. Which donor or graft source should you choose for the strongest GVL? Is there really any difference? Best. Pr Res Clin Haematol. 2013;26:293\u20136.","journal-title":"Pr Res Clin Haematol"},{"key":"2823_CR33","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41375-024-02445-x","volume":"39","author":"A Shimoni","year":"2025","unstructured":"Shimoni A, Peczynski C, Labopin M, Kulagin A, Meijer E, Cornelissen J, et al. Post-transplant cyclophosphamide separates graft-versus-host disease and graft-versus-leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemia. Leukemia. 2025;39:222\u20138.","journal-title":"Leukemia"},{"key":"2823_CR34","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/s41409-021-01493-6","volume":"57","author":"A Shimoni","year":"2022","unstructured":"Shimoni A, Labopin M, Angelucci E, Blaise D, Ciceri F, Koc Y, et al. The association of graft-versus-leukemia effect and graft-versus-host disease in haploidentical transplantation with post-transplant cyclophosphamide for AML. Bone Marrow Transpl. 2022;57:384\u201390.","journal-title":"Bone Marrow Transpl"},{"key":"2823_CR35","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13045-023-01403-x","volume":"16","author":"F Baron","year":"2023","unstructured":"Baron F, Labopin M, Tischer J, Raiola AM, Vydra J, Blaise D, et al. GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT. J Hematol Oncol. 2023;16:10.","journal-title":"J Hematol Oncol"},{"key":"2823_CR36","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.3390\/jcm10132843","volume":"10","author":"N Sharma","year":"2021","unstructured":"Sharma N, Faisal MS, Zhao Q, Jiang J, Edler P, Benson DM, et al. Outcomes of bone marrow compared to peripheral blood for haploidentical transplantation. J Clin Med. 2021;10:2843.","journal-title":"J Clin Med"},{"key":"2823_CR37","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1002\/ajh.26627","volume":"97","author":"F Baron","year":"2022","unstructured":"Baron F, Labopin M, Tischer J, Ciceri F, Raiola AM, Blaise D, et al. Human leukocyte antigen-haploidentical transplantation for relapsed\/refractory acute myeloid leukemia: Better leukemia-free survival with bone marrow than with peripheral blood stem cells in patients\u2009\u226555\u2009years of age. Am J Hematol. 2022;97:1065\u201374.","journal-title":"Am J Hematol"},{"key":"2823_CR38","doi-asserted-by":"publisher","first-page":"4877","DOI":"10.1182\/blood-2024-200005","volume":"144","author":"M Mushtaq","year":"2024","unstructured":"Mushtaq M, Kasaeian A, Chaudhary SG, Amin MK, Khavandgar N, Alemi H, et al. Outcomes after bone marrow versus peripheral blood haploidentical hematopoietic cell transplantation using posttransplant cyclophosphamide-based GVHD prophylaxis. Blood. 2024;144:4877.","journal-title":"Blood"},{"key":"2823_CR39","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1002\/ajh.25087","volume":"9","author":"Z Li","year":"2018","unstructured":"Li Z, Labopin M, Ciceri F, Blaise D, Tischer J, Ehninger G, et al. Haploidentical transplantation outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) study. Am J Hematol. 2018;9:769\u201377.","journal-title":"Am J Hematol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02823-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02823-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02823-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:50:18Z","timestamp":1778154618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02823-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2823"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02823-2","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. The scientific boards of the ALWP of the EBMT approved this study. Informed consent was obtained from all subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}